Program
ertugliflozin
Also written as “Ertugliflozin 5 mg”, “Ertugliflozin” and “Ertugliflozin 15 mg”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Fatty Liver · Renal Insufficiency, led by 3 companies.
Drug pageErtugliflozin: every studyAll 37 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merckits history only | 200 open or running | phase 3since Oct 7, 2013 | Oct 1, 2009 | none ahead |
| Getz Pharma | 11 open or running | phase 4since Nov 18, 2022 | Nov 18, 2022 | none ahead |
| Humanis Saglık Anonim Sirketiits history only | 10 open or running | phase 1since Dec 3, 2025 | Dec 3, 2025 | none ahead |
Also a collaborator on its studies: Pfizer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Getz Pharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 18, 2022First study: phase 4 study in Fatty LiverFirst studyNCT05644717 · 164 planned · Pakistan
TargetBeta
“Sodium/glucose cotransporter 2 inhibitor; Sodium/glucose cotransporter 2 inhibitor”ChEMBL 37, by rule
Other programs on SLC5A2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| empagliflozinrule | Boehringer Ingelheim | phase 4 | 142 |
| dapagliflozin | AstraZeneca | phase 4 | 133 |
| vicadrostat | Boehringer Ingelheim | phase 3 | 16 |
| Empagliflozin/Linagliptinrule | Humanis Saglık Anonim Sirketi | phase 1 | 2 |
Studies
The one study Getz Pharma leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05644717Fatty Liver · Pakistan | 4 | Recruiting | Nov 1, 2025 | 164 |
How it is read
Names in the registry
- “Ertugliflozin 5 mg”, 10 entries
- “Ertugliflozin”, 8 entries
- “Ertugliflozin 15 mg”, 5 entries
- “Ertugliflozin 10 mg”, 4 entries
- “Ertugliflozin 1 mg”, 2 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 18 studies
- Fatty Liver, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.